Published in World J Nephrol on November 06, 2013
A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int (2014) 1.33
Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR. Case Rep Nephrol (2014) 0.91
Podocyturia: What is in a name? J Transl Int Med (2015) 0.88
Copious Podocyturia without Proteinuria and with Normal Renal Function in a Young Adult with Fabry Disease. Case Rep Nephrol (2015) 0.84
Podocyte directed therapy of nephrotic syndrome-can we bring the inside out? Pediatr Nephrol (2015) 0.78
Urokinase gene 3'-UTR T/C polymorphism is associated with malignancy and ESRD in idiopathic membranous nephropathy. Biomed Res Int (2014) 0.75
Podocyturia: Potential applications and current limitations. World J Nephrol (2017) 0.75
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med (2008) 5.01
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med (2011) 3.19
Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem (1994) 2.92
Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol (2012) 2.83
Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem (1991) 2.68
Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol (2008) 2.64
Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol (2008) 2.57
suPAR: the molecular crystal ball. Dis Markers (2009) 2.55
Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol (2010) 2.52
Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int (2010) 2.47
A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol (1999) 2.46
The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol (1990) 2.36
Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med (2010) 2.32
Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol (2005) 2.25
Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2010) 2.24
The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A (2002) 2.14
Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation (2013) 2.10
Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol (2000) 2.09
Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell (2001) 2.09
Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol (2005) 2.08
Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol (1997) 2.04
Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations. Kidney Int (2007) 1.86
Plasmin activates epithelial Na+ channels by cleaving the gamma subunit. J Biol Chem (2008) 1.86
The podocyte cytoskeleton--key to a functioning glomerulus in health and disease. Nat Rev Nephrol (2011) 1.86
Structure of human urokinase plasminogen activator in complex with its receptor. Science (2006) 1.84
Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol (2008) 1.72
Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J (1996) 1.70
Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med (1998) 1.57
Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol (2006) 1.53
The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem (1991) 1.52
Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J (2003) 1.52
Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev (2004) 1.51
Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy. Arch Pathol Lab Med (2009) 1.49
Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest (1997) 1.49
A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J (1997) 1.47
Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol (2011) 1.47
Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC. Pediatr Nephrol (2013) 1.46
A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome. Biomedicine (1975) 1.39
uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today (1997) 1.36
Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol (1988) 1.32
Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int (2001) 1.26
ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem (1997) 1.26
Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant (2009) 1.24
Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes. J Am Soc Nephrol (2008) 1.18
Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol (2008) 1.18
Focal and segmental glomerulosclerosis in children: a longitudinal assessment. Pediatr Nephrol (2007) 1.17
Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant (2011) 1.17
Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem (1997) 1.16
Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis (2004) 1.15
Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol (2013) 1.13
Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest (1999) 1.10
Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatr Nephrol (2005) 1.08
Treatment of primary focal segmental glomerulosclerosis. Kidney Int (2002) 1.06
High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis (2004) 1.06
Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett (2000) 1.04
Focal segmental glomerulosclerosis: pathogenesis and treatment. Curr Opin Pediatr (2003) 1.03
Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol (1997) 1.03
Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children. Transplantation (2003) 1.02
Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome. J Lab Clin Med (1994) 1.01
Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol (2006) 0.99
Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol (2004) 0.93
Protease activity of plasma hemopexin. Kidney Int (2005) 0.92
High-dose cyclosporine therapy in recurrent nephrotic syndrome following renal transplantation. Transplantation (1990) 0.92
Transforming growth factor-beta1 inhibits vascular permeability factor release by T cells in normal subjects and in patients with minimal-change nephrotic syndrome. Nephron (2001) 0.88
Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients. Thromb Res (2001) 0.85
Posttransplant recurrence of proteinuria in a case of focal segmental glomerulosclerosis associated with WT1 mutation. Am J Transplant (2006) 0.83
Urinary plasmin inhibits TRPV5 in nephrotic-range proteinuria. J Am Soc Nephrol (2012) 0.82
Recurrence of proteinuria following renal transplantation in congenital nephrotic syndrome of the Finnish type. Pediatr Nephrol (2006) 0.81
A suPAR circulating factor causes kidney disease. Nat Med (2011) 0.80
Therapeutic apheresis rescue mission: recurrent focal segmental glomerulosclerosis in renal allografts. Semin Dial (2011) 0.79
Recurrent and de novo renal disease after kidney transplantation with or without cyclosporine A. Am J Kidney Dis (1991) 0.78
suPAR and FSGS: the gap between bench and bedside. Transplantation (2013) 0.78